TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an update.
Simcere Pharmaceutical Group Limited announced an exclusive license agreement with Vigonvita Life Science Co., Ltd. for Deuterated Remdesivir Hydrobromide, targeting new indications in the Greater China region for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. This agreement enhances Simcere’s product portfolio in the anti-infection area, leveraging positive Phase II clinical trial results and a Breakthrough Therapy designation in China, which may strengthen its market position and benefit stakeholders.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company focused on therapeutic areas such as neuroscience, anti-oncology, autoimmune, and anti-infection. The company has established a State Key Laboratory of Neurology and Oncology Drug Development and aims to address significant clinical needs through strategic partnerships and in-house R&D efforts.
Average Trading Volume: 10,754,079
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.16B
For detailed information about 2096 stock, go to TipRanks’ Stock Analysis page.